YOLFTbeta
Shanghai Shyndec Pharmaceutical Co Ltd

Shanghai Shyndec Pharmaceutical Co Ltd

600420 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

7.97CNY-0.10 (-1.24%)

Price History

Full chart

Market Stats

Previous Close8.07
Open8.07
Day Range7.97 – 8.10
52-Week Range7.67 – 11.09
Volume7.29M
Market Cap11.25B
P/E (TTM)20.46
Forward P/E34.97
EPS0.41
Dividend Yield2.98%
Beta0.08
50-Day Avg8.55
200-Day Avg9.52

About

Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company provides nifedipine controlled release tablets, penicillin industrial potassium salt, touboke yuekui granules/capsules, sodium cefuroxime for injection, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, and cefoperazone dispersible tablets; and cefuroxime axetil tablets, cefuroxime sodium for injection, cefaclor extended-release capsules, cefixime granules, and cefdinir dispersible tablets. It also offers nifedipine controlled-release tablets, amlodipine besylate tablets, enalapril maleate tablet, pravastatin sodium tablets, olmesartan medoxomil hydrochlorothiazide tablets, olmesartan amlodipine tablets; milnaprom hydrochloride tablets, lofen codeine tablets, gastrodin injection, naloxone hydrochloride injection, piracetam injection; and apmis film, tacrolimus capsules, mannan peptide for injection, imatinib mesylate. In addition, the company provides methylprednisolone sodium succinate for injection, octreotide acetate injection, betamethasone sodium phosphate for injection, dexamethasone sodium phosphate injection; diclofenac sodium sustained release tablets; 6-aminopenicillinic acid, azithromycin, amoxicillin, potassium clavulanate microcrystalline cellulose, ceftriaxone sodium crude salt, 7-aminocephalosporanic acid, chorionic gonadotropin, urinary gonadotropin; and naphazoline hydrochloride nasal drops, Ambroxol Hydrochloride Oral Solution. Shanghai Shyndec Pharmaceutical Co., Ltd. was founded in 1996 and is based in Shanghai, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Yong Liu
  • Employees9.70K
  • HeadquartersNo. 378, Jianlu Road, Shanghai, China, 200137, China
  • Websitehttps://www.shyndec.com

Leadership

  • Mr. Yong LiuPresident & Director · b. 1969
  • Mr. Xiangchen WangChief Financial Officer · b. 1972
  • Mr. Zhongxi ZhangVP, General Counsel, Chief Compliance Officer & Board Secretary · b. 1976
  • Cai Zheng yanVice President
  • Lei GaoAccounting Supervisor

Financials

Income Statement

Currency: CNY2001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue149.10M227.58M382.91M358.53M502.75M545.87M624.32M678.30M1.16B1.42B1.70B2.20B2.35B2.75B8.99B9.13B8.52B11.32B12.20B12.56B13.94B12.96B12.07B10.94B9.36B
Growth (%)-+52.64%+68.25%-6.37%+40.22%+8.58%+14.37%+8.65%+71.64%+22.22%+19.65%+29.31%+6.73%+16.98%+226.96%+1.54%-6.66%+32.91%+7.76%+2.93%+11.06%-7.07%-6.86%-9.38%-14.40%
Cost of Revenue68.56M137.93M262.18M216.26M316.30M354.92M397.72M436.53M817.92M987.46M1.17B1.45B1.37B1.50B5.92B5.91B4.89B5.86B6.24B6.77B7.91B8.09B7.54B6.82B6.33B
Gross Profit80.54M89.65M120.74M142.28M186.45M190.95M226.61M250.71M346.31M435.50M529.09M748.79M976.44M1.25B3.07B3.21B3.63B5.46B5.96B5.79B6.04B4.87B4.53B4.12B9.36B
Gross Margin54.02%39.39%31.53%39.68%37.09%34.98%36.30%36.96%29.75%30.61%31.07%34.01%41.56%45.59%34.11%35.21%42.58%48.20%48.86%46.12%43.28%37.57%37.55%37.63%100.00%
Operating Expense62.44M59.61M83.74M86.70M107.19M115.83M98.09M169.84M234.90M295.98M375.35M559.30M796.27M1.00B2.08B2.31B2.70B4.17B4.93B4.77B5.14B3.90B3.45B2.36B8.05B
Operating Income18.10M30.04M36.99M55.58M79.25M75.12M128.51M80.87M111.41M139.52M153.74M189.50M180.17M252.97M989.08M898.38M922.85M1.28B1.03B1.02B897.56M966.14M1.08B1.75B1.31B
Operating Margin12.14%13.20%9.66%15.50%15.76%13.76%20.58%11.92%9.57%9.80%9.03%8.61%7.67%9.20%11.00%9.84%10.83%11.32%8.45%8.16%6.44%7.46%8.96%16.02%14.03%
EBITDA21.40M34.40M39.99M70.39M98.44M97.06M154.39M107.59M153.81M187.86M218.52M284.60M316.99M459.78M1.84B2.07B2.03B2.24B1.99B1.90B1.81B1.93B1.98B2.46B2.08B
EBITDA Margin14.36%15.12%10.44%19.63%19.58%17.78%24.73%15.86%13.21%13.20%12.83%12.93%13.49%16.73%20.48%22.64%23.83%19.76%16.35%15.14%12.96%14.86%16.38%22.53%22.22%
Net Income14.58M21.90M23.43M36.83M58.69M50.89M94.03M53.91M89.05M108.11M120.03M127.87M132.79M189.99M529.99M476.93M515.80M705.52M656.37M648.79M568.28M627.79M691.88M1.08B944.38M
Net Income Margin9.78%9.62%6.12%10.27%11.67%9.32%15.06%7.95%7.65%7.60%7.05%5.81%5.65%6.91%5.90%5.23%6.06%6.23%5.38%5.17%4.08%4.84%5.73%9.91%10.09%
R&D---------41.04M36.69M51.14M85.79M93.87M276.45M365.29M319.17M373.64M417.17M498.93M589.18M520.92M569.43M598.10M441.79M
R&D as % of Total Revenue---------2.88%2.15%2.32%3.65%3.42%3.08%4.00%3.75%3.30%3.42%3.97%4.23%4.02%4.72%5.47%4.72%
Interest Expense523.93K1.03M1.94M2.20M256.87K475.00K824.15K1.40M1.98M2.55M8.67M20.36M26.24M57.99M92.88M305.38M261.76M211.62M199.61M133.11M110.47M111.54M61.97M38.90M4.39M
Interest Expense % of Total Revenue0.35%0.45%0.51%0.61%0.05%0.09%0.13%0.21%0.17%0.18%0.51%0.92%1.12%2.11%1.03%3.35%3.07%1.87%1.64%1.06%0.79%0.86%0.51%0.36%0.05%

Balance Sheet

Currency: CNY2001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets175.79M203.58M262.10M516.19M585.51M597.64M713.86M794.87M927.71M1.14B1.49B2.47B3.15B3.81B4.14B15.02B15.17B16.46B17.64B18.25B19.07B19.63B19.35B19.96B19.23B
Total Liabilities80.67M88.90M119.11M74.32M106.67M86.15M119.57M163.41M214.24M298.05M544.70M1.28B1.82B2.42B2.53B8.08B7.52B8.02B8.44B8.43B8.70B7.48B5.01B4.63B-15.70B
Total Equity78.98M95.69M114.16M401.60M431.21M453.47M523.73M551.49M615.45M723.56M814.82M903.64M995.18M1.17B1.33B5.70B6.17B6.81B7.59B8.13B8.59B10.31B12.39B13.20B15.70B
Cash34.86M20.96M34.21M220.41M185.72M143.15M177.24M177.04M200.09M163.25M275.58M496.25M433.31M366.23M422.01M1.64B2.44B3.83B5.16B3.72B4.28B6.15B5.97B6.21B4.01B
Total Debt21.20M42.80M65.80M11.00M23.00M8.00M17.00M45.00M38.00M46.00M203.78M596.65M1.09B1.63B1.86B4.94B4.10B3.73B4.30B3.15B3.58B3.40B1.13B1.74B-
Net Debt-13.66M21.84M31.59M-209.41M-162.72M-135.15M-160.24M-132.04M-162.09M-117.25M-71.81M100.40M653.98M1.27B1.43B3.30B1.66B-98.00M-865.84M-572.66M-707.55M-2.74B-4.84B-5.07B-

Cash Flow

Currency: CNY2001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow---17.02M57.90M73.60M82.31M58.04M97.43M115.11M136.12M193.41M207.50M258.51M226.65M838.58M2.31B1.67B1.27B1.56B1.68B2.86B1.72B2.26B1.70B
Investing Cash Flow--36.80M-19.43M-22.95M-71.17M-70.89M-23.40M-60.62M-64.73M-151.50M-127.99M-382.23M-580.85M-721.75M-235.23M-64.55M-138.75M51.19M-333.28M-557.09M-508.28M-302.44M-1.36B-856.23M-
Financing Cash Flow-15.46M15.56M192.12M-21.16M-45.16M-24.73M-8.48M-21.07M-3.55M111.78M322.42M344.12M438.41M25.07M-260.23M-1.38B-652.60M-140.87M-1.97B-662.41M-435.32M-1.09B-415.42M-
Capital Expenditure035.42M19.68M15.79M71.65M62.00M34.45M13.56M31.29M156.02M128.40M405.52M512.62M430.53M234.52M241.30M168.44M399.40M403.82M377.98M521.44M307.44M357.19M219.77M263.83M
Free Cash Flow--35.42M-19.68M1.23M-13.75M11.60M47.86M44.49M66.14M-40.91M7.72M-212.11M-305.13M-172.02M-7.87M597.27M2.15B1.27B866.32M1.18B1.16B2.55B1.36B2.04B1.43B
Dividends Paid-7.63M7.57M2.23M33.84M26.66M26.98M27.48M7.07M2.55M46.00M64.45M52.30M87.86M158.25M467.81M395.77M456.89M105.62M102.69M212.46M102.70M189.35M300.68M427.90M
FCF to OCF---7.21%-23.75%15.76%58.14%76.64%67.88%-35.54%5.67%-109.67%-147.05%-66.54%-3.47%71.22%92.72%76.07%68.21%75.77%68.96%89.23%79.24%90.26%84.46%
Dividend Paid to FCF--21.55%-38.48%181.77%-246.11%229.85%56.38%61.78%10.70%-6.23%595.67%-30.39%-17.14%-51.08%-2010.19%78.32%18.44%35.98%12.19%8.69%18.34%4.03%13.89%14.77%29.83%

Earnings

Report DateMar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Oct 24, 2013Mar 27, 2014May 28, 2014Aug 19, 2014Oct 30, 2014Jan 15, 2015Apr 30, 2015Aug 7, 2015Oct 29, 2015Jan 28, 2016Apr 28, 2016Aug 30, 2016Oct 21, 2016Jan 20, 2017Apr 20, 2017Jul 20, 2017Oct 24, 2017Jan 22, 2018Apr 18, 2018Aug 17, 2018Oct 26, 2018Apr 18, 2019Jul 23, 2019Oct 25, 2019Mar 25, 2020Apr 1, 2020Aug 28, 2020Oct 28, 2020Mar 26, 2021Apr 29, 2021Aug 27, 2021Oct 29, 2021Mar 25, 2022Apr 30, 2022Aug 31, 2022Oct 28, 2022Mar 30, 2023Apr 29, 2023Apr 29, 2024Aug 27, 2024Oct 28, 2024Mar 27, 2025Apr 28, 2025Jul 17, 2025
EPS Estimate--------------0.050.09-------------------0.07----------------0.100.250.220.110.260.29
EPS Actual0.050.040.050.050.050.040.030.090.050.040.040.070.060.060.040.010.070.110.040.110.090.120.030.140.070.090.040.640.140.180.080.060.160.210.15-0.130.180.190.080.070.160.260.020.190.170.17-0.060.070.130.170.170.140.250.290.170.100.270.23
Surprise---------------20.00%-88.89%--------------------285.71%----------------150.00%16.00%-22.73%-9.09%3.85%-20.69%
Timing--------------After-hoursAfter-hours-After-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-market-Pre-market------Pre-marketPre-market----After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-market

Key Statistics & Ratios

Market Cap11.25B
Enterprise Value7.71B
Trailing P/E20.46
Forward P/E34.97
Price / Sales1.34
Price / Book0.81
EPS0.41
Book Value10.28
Revenue (TTM)8.43B
Gross Profit (TTM)2.35B
EBITDA1.36B
Profit Margin6.47%
Operating Margin7.29%
Return on Equity4.65%
Return on Assets2.07%
Shares Outstanding1.34B
Shares Float559.91M
Beta0.08
Dividend Yield2.98%
Dividend Rate0.25
Payout Ratio123.00%

Dividends

20231×
0.10Jul 6, 2023
20221×
0.10Jul 29, 2022
20211×
0.10Jun 25, 2021
20201×
0.10Jun 24, 2020
20191×
0.10Jun 26, 2019
20181×
0.05Jun 14, 2018
20171×
0.26May 25, 2017
20161×
0.03Jun 24, 2016
20151×
0.10Jun 12, 2015
20121×
0.05Jul 11, 2012
20111×
0.05Mar 2, 2011
20081×
0.05Apr 11, 2008
20071×
0.05Jun 25, 2007
20062×
0.09May 25, 20060.51Apr 3, 2006
20051×
0.04Jun 15, 2005

Stock Splits

  • May 25, 20172:1
  • Apr 11, 200811:10
  • May 25, 20062:1
  • Apr 3, 20065:4
  • Jun 15, 20053:2